RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies

Risultato della ricerca: Articlepeer review

2 Citazioni (Scopus)

Abstract

The hypothesis that been set forward that use of Renin Angiotensin Aldosterone System (RAAS) inhibitors is associated with COVID-19 severity. We set-up a multicenter Italian collaboration (CORIST Project, ClinicalTrials.gov ID: NCT04318418) to retrospectively investigate the relationship between RAAS inhibitors and COVID-19 in-hospital mortality. We also carried out an updated meta-analysis on the relevant studies.
Lingua originaleEnglish
Numero di pagine10
RivistaVascular Pharmacology
Volume135
Stato di pubblicazionePublished - 2020

All Science Journal Classification (ASJC) codes

  • Physiology
  • Molecular Medicine
  • Pharmacology

Cita questo